On May 9, 2024, the Philips Defendants and Plaintiffs’ Negotiating Counsel (“Parties”) entered into a Master Settlement Agreement (“MSA”) to resolve actual asserted claims or potential Personal Injury Claims against the Philips Defendants concerning certain recalled CPAP, BIPAP and ventilator products (“Recalled Devices”).

You may have heard about the 2021 voluntary Philips Respironics recall notification* related to certain CPAP and BiPAP sleep therapy devices and ventilators, and you may have questions about related litigation .

2025年1月20日 · The FDA has announced that Philips Respironics is recalling certain refurbished DreamStation CPAP and BiPAP machines due to the risk of delivering inaccurate or insufficient therapy. These are machines that have presumably been fixed after the recall.

2025年1月2日 · Philips CPAP lawsuits claim people who used devices included in the 2021 CPAP recall developed cancer, lung problems or other injuries due to degraded foam. Philips Respironics agreed to a $1.1 billion settlement on April 29, 2024, to compensate people for financial damages related to the recall.

The CPAP Philips MDL Settlement website provides information and assistance to those affected by the recall of Philips Respironics CPAP devices.

Philips Respironics Sleep and Respiratory Care devices. In June 2021, after discovering a potential health risk related to the foam in certain CPAP, BiPAP and Mechanical Ventilator devices, Philips Respironics issued a voluntary Field Safety Notice (outside U.S.) / voluntary recall notification (U.S. only).

2024年11月20日 · In June 2021, Philips Respironics (Philips) recalled certain ventilators, bi-level positive airway pressure (also known as Bilevel PAP, BiPAP, or BPAP) machines, and continuous positive...

This will resolve all Philips Respironics CPAP-related lawsuits filed in the federal multidistrict litigation (MDL 3014) before the Honorable Judge Joy Flowers and those filed in Massachusetts state court. The Settlement Program also resolves any tolled or unfiled claims against the Philips Defendants as set forth in the MSA.

Philips Respironics acted to protect patient safety by initiating and executing a voluntary recall* of significant scale in June 2021. Philips regrets any distress and concern this recall* has caused patients, their families and care providers.

The complaint, filed by the Department of Justice on behalf of the FDA, alleged that Philips Respironics violated the Federal Food, Drug, and Cosmetic Act (FD&C Act) by introducing devices into...